{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T10:11:08Z","timestamp":1794219068640,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T00:00:00Z","timestamp":1745971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["RG.LIGH.118431"],"award-info":[{"award-number":["RG.LIGH.118431"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Aims\/hypothesis<\/jats:title>\n            <jats:p>Individuals with type 1 diabetes are at increased cardiovascular risk, particularly in the presence of insulin resistance. A prothrombotic environment is believed to contribute to this risk but thrombotic pathways in type 1 diabetes are only partially understood and the role of platelets is incompletely studied. We hypothesised that platelets from individuals with type 1 diabetes exhibit platelet hyperactivity due to both increased propensity for activation and diminished sensitivity to inhibition, with an amplified maladaptive phenotype in those with insulin resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Blood samples were obtained from individuals with type 1 diabetes enrolled on the \u2018Double diabEtes and adVErse cLinical Outcome: identification of mechanistic Pathways\u2019 (DEVELOP) study with insulin resistance assessed as estimated glucose disposal rate (eGDR), whereby eGDR &gt;8 or &lt;6 mg kg<jats:sup>\u22121<\/jats:sup> min<jats:sup>\u22121<\/jats:sup> indicates normal insulin sensitivity or advanced insulin resistance, respectively. Platelet function was analysed using whole blood multiparameter flow cytometry to simultaneously measure three distinct markers of activation, including integrin \u03b1<jats:sub>IIb<\/jats:sub>\u03b2<jats:sub>3<\/jats:sub> (PAC-1 binding), P-selectin (CD62P) and phosphatidylserine (PS) (Annexin V). Both activation and inhibition responses of the platelets were investigated, which were subjected to the machine learning tool Full Annotation Shape-constrained Trees (FAUST) to characterise platelet subpopulations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 32 individuals with type 1 diabetes were studied (median age [range] of 24 [18\u201334] years, 59% male, diabetes duration [mean\u00a0\u00b1\u00a0SD] of 14.0\u00a0\u00b1\u00a06.3 years and HbA<jats:sub>1c<\/jats:sub> of 65.3\u00a0\u00b1\u00a014.0 mmol\/mol [8.1%]). An increased basal expression, measured as mean fluorescence intensity, of all three platelet activation markers was detected in the type 1 diabetes group compared with healthy control participants (CD62P expression 521\u00a0\u00b1\u00a0246 vs 335\u00a0\u00b1\u00a067; <jats:italic>p<\/jats:italic>&lt;0.001, PAC-1 370\u00a0\u00b1\u00a0165 vs 231\u00a0\u00b1\u00a088; <jats:italic>p<\/jats:italic>=0.011 and PS 869\u00a0\u00b1\u00a0762 vs 294\u00a0\u00b1\u00a0109; <jats:italic>p<\/jats:italic>=0.001). Following platelet stimulation, an enhanced activation of these markers was found in the type 1 diabetes group. Within the type 1 diabetes group, those with advanced insulin resistance (eGDR&lt;6 mg kg<jats:sup>\u22121<\/jats:sup> min<jats:sup>\u22121<\/jats:sup>) showed increased platelet activation compared with individuals with normal insulin sensitivity (eGDR&gt;8 mg kg<jats:sup>\u22121<\/jats:sup> min<jats:sup>\u22121<\/jats:sup>) with single agonist stimulation CD62P expression (29,167\u00a0\u00b1\u00a02177 vs 22,829\u00a0\u00b1\u00a02535, <jats:italic>p<\/jats:italic>&lt;0.001 and PAC-1 19,339\u00a0\u00b1\u00a011,749 and 5187\u00a0\u00b1\u00a02872, <jats:italic>p<\/jats:italic>=0.02). Moreover, individuals with type 1 diabetes showed reduced sensitivity to platelet inhibition by prostacyclin (PGI<jats:sub>2<\/jats:sub>) compared with control participants. Stratification of individuals with type 1 diabetes by insulin resistance demonstrated that in the presence of PGI<jats:sub>2<\/jats:sub>, suppression of stimulated CD62P was 17\u00a0\u00b1\u00a011% and 33\u00a0\u00b1\u00a012% (<jats:italic>p<\/jats:italic>=0.02) for advanced insulin resistance and normal insulin sensitivity groups, respectively, with even larger differences demonstrated for PAC-1 (48\u00a0\u00b1\u00a017% and 75\u00a0\u00b1\u00a07%; <jats:italic>p<\/jats:italic>=0.006) and PS exposure (33\u00a0\u00b1\u00a012% and 84\u00a0\u00b1\u00a010%; <jats:italic>p<\/jats:italic>=0.001). Furthermore, FAUST analysis showed that, under basal conditions, there was a different distribution of the eight platelet subpopulations comparing advanced insulin resistance and normal insulin sensitivity groups, with differences also detected following PGI<jats:sub>2<\/jats:sub> inhibition.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\/interpretation<\/jats:title>\n            <jats:p>Our novel characterisation of platelets in type 1 diabetes shows a maladaptive phenotype with increased basal activity together with hyperactivation following stimulation and diminished responses to inhibition. Insulin resistance appears to further drive this adverse thrombotic phenotype, suggesting an enhanced platelet-driven cardiovascular risk in those with type 1 diabetes and reduced insulin sensitivity.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical Abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1007\/s00125-025-06429-z","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T11:16:59Z","timestamp":1746011819000},"page":"1544-1558","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Insulin resistance in type 1 diabetes is a key modulator of platelet hyperreactivity"],"prefix":"10.1007","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7972-3321","authenticated-orcid":false,"given":"Rebecca C.","family":"Sagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisie M.","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam M.","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noppadol","family":"Kietsiriroje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Hindle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lih T.","family":"Cheah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramzi A.","family":"Ajjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid M.","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,30]]},"reference":[{"issue":"11","key":"6429_CR1","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.2337\/dc06-1161","volume":"29","author":"TJ Orchard","year":"2006","unstructured":"Orchard TJ, Costacou T, Kretowski A, Nesto RW (2006) Type 1 diabetes and coronary artery disease. Diabetes Care 29(11):2528\u20132538. https:\/\/doi.org\/10.2337\/dc06-1161","journal-title":"Diabetes Care"},{"issue":"10","key":"6429_CR2","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2337\/dc14-1720","volume":"37","author":"SD de Ferranti","year":"2014","unstructured":"de Ferranti SD, de Boer IH, Fonseca V et al (2014) Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care 37(10):2843\u20132863. https:\/\/doi.org\/10.2337\/dc14-1720","journal-title":"Diabetes Care"},{"issue":"10","key":"6429_CR3","doi-asserted-by":"publisher","first-page":"e1001321","DOI":"10.1371\/journal.pmed.1001321","volume":"9","author":"SJ Livingstone","year":"2012","unstructured":"Livingstone SJ, Looker HC, Hothersall EJ et al (2012) Risk of cardiovascular disease and total mortality in adults with type 1 diabetes: Scottish registry linkage study. PLOS Med 9(10):e1001321. https:\/\/doi.org\/10.1371\/journal.pmed.1001321","journal-title":"PLOS Med"},{"issue":"20","key":"6429_CR4","doi-asserted-by":"publisher","first-page":"15328","DOI":"10.3390\/ijms242015328","volume":"24","author":"NZ Safdar","year":"2023","unstructured":"Safdar NZ, Kietsiriroje N, Ajjan RA (2023) The cellular and protein arms of coagulation in diabetes: established and potential targets for the reduction of thrombotic risk. Int J Mol Sci 24(20):15328. https:\/\/doi.org\/10.3390\/ijms242015328","journal-title":"Int J Mol Sci"},{"issue":"6","key":"6429_CR5","doi-asserted-by":"publisher","first-page":"733","DOI":"10.7326\/0003-4819-82-6-733","volume":"82","author":"J Sagel","year":"1975","unstructured":"Sagel J, Colwell JA, Crook L, Laimins M (1975) Increased platelet aggregation in early diabetus mellitus. Ann Intern Med 82(6):733\u2013738. https:\/\/doi.org\/10.7326\/0003-4819-82-6-733","journal-title":"Ann Intern Med"},{"issue":"4","key":"6429_CR6","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/0026-0495(79)90044-1","volume":"28","author":"JA Colwell","year":"1979","unstructured":"Colwell JA, Nair RMG, Halushka PV, Rogers C, Whetsell A, Sagel J (1979) Platelet adhesion and aggregation in diabetes mellitus. Metab Clin Exp 28(4):394\u2013400. https:\/\/doi.org\/10.1016\/0026-0495(79)90044-1","journal-title":"Metab Clin Exp"},{"issue":"7","key":"6429_CR7","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.2337\/diacare.26.7.2181","volume":"26","author":"JA Colwell","year":"2003","unstructured":"Colwell JA, Nesto RW (2003) The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 26(7):2181\u20132188. https:\/\/doi.org\/10.2337\/diacare.26.7.2181","journal-title":"Diabetes Care"},{"key":"6429_CR8","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618805861","author":"AM Zahran","year":"2018","unstructured":"Zahran AM, El-Badawy O, Mohamad IL, Tamer DM, Abdel-Aziz SM, Elsayh KI (2018) Platelet activation and platelet-leukocyte aggregates in type I diabetes mellitus. Clin Appl Thromb Hemost. https:\/\/doi.org\/10.1177\/1076029618805861","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"6429_CR9","doi-asserted-by":"publisher","first-page":"e008522","DOI":"10.1161\/JAHA.118.008522","volume":"7","author":"MK Puurunen","year":"2018","unstructured":"Puurunen MK, Hwang SJ, Larson MG et al (2018) ADP platelet hyperreactivity predicts cardiovascular disease in the FHS (Framingham Heart Study). J Am Heart Assoc 7(5):e008522. https:\/\/doi.org\/10.1161\/JAHA.118.008522","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"6429_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s11886-012-0280-z","volume":"14","author":"A Nusca","year":"2012","unstructured":"Nusca A, Patti G (2012) Platelet function and inhibition in ischemic heart disease. Curr Cardiol Rep 14(4):457\u2013467. https:\/\/doi.org\/10.1007\/s11886-012-0280-z","journal-title":"Curr Cardiol Rep"},{"issue":"11","key":"6429_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1055\/s-2007-1018778","volume":"15","author":"T Akai","year":"1983","unstructured":"Akai T, Naka K, Okuda K, Takemura T, Fujii S (1983) Decreased sensitivity of platelets to prostacyclin in patients with diabetes mellitus. Horm Metab Res 15(11):523\u2013526. https:\/\/doi.org\/10.1055\/s-2007-1018778","journal-title":"Horm Metab Res"},{"issue":"2","key":"6429_CR12","first-page":"229","volume":"14","author":"PK Pillay","year":"1985","unstructured":"Pillay PK, Pillay U, Balasubramaniam P, Lee KO (1985) Platelet sensitivity to prostacyclin in diabetes mellitus. Ann Acad Med Singap 14(2):229\u2013231","journal-title":"Ann Acad Med Singap"},{"issue":"5","key":"6429_CR13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/j.1365-2362.1982.tb00686.x","volume":"12","author":"DJ Betteridge","year":"1982","unstructured":"Betteridge DJ, El Tahir KE, Reckless JP, Williams KI (1982) Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Eur J Clin Invest 12(5):395\u2013398. https:\/\/doi.org\/10.1111\/j.1365-2362.1982.tb00686.x","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"6429_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12933-018-0763-3","volume":"17","author":"R Kaur","year":"2018","unstructured":"Kaur R, Kaur M, Singh J (2018) Endothelial dysfunction and platelet hyperactivity in type 2 diabetes mellitus: molecular insights and therapeutic strategies. Cardiovasc Diabetol 17(1):121. https:\/\/doi.org\/10.1186\/s12933-018-0763-3","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"6429_CR15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2003.08.033","volume":"92","author":"FK Keating","year":"2003","unstructured":"Keating FK, Sobel BE, Schneider DJ (2003) Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 92(11):1362\u20131365. https:\/\/doi.org\/10.1016\/j.amjcard.2003.08.033","journal-title":"Am J Cardiol"},{"issue":"4","key":"6429_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2337\/dc08-1865","volume":"32","author":"DJ Schneider","year":"2009","unstructured":"Schneider DJ (2009) Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 32(4):525\u2013527. https:\/\/doi.org\/10.2337\/dc08-1865","journal-title":"Diabetes Care"},{"issue":"4","key":"6429_CR17","doi-asserted-by":"publisher","first-page":"626","DOI":"10.2337\/diabetes.49.4.626","volume":"49","author":"KV Williams","year":"2000","unstructured":"Williams KV, Erbey JR, Becker D, Arslanian S, Orchard TJ (2000) Can clinical factors estimate insulin resistance in type 1 diabetes? Diabetes 49(4):626\u2013632. https:\/\/doi.org\/10.2337\/diabetes.49.4.626","journal-title":"Diabetes"},{"issue":"3","key":"6429_CR18","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/dom.13110","volume":"20","author":"T Nystr\u00f6m","year":"2018","unstructured":"Nystr\u00f6m T, Holzmann MJ, Eliasson B, Svensson A-M, Sartipy U (2018) Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab 20(3):556\u2013563. https:\/\/doi.org\/10.1111\/dom.13110","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"6429_CR19","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1111\/dom.13848","volume":"21","author":"N Kietsiriroje","year":"2019","unstructured":"Kietsiriroje N, Pearson S, Campbell M, Ari\u00ebns RAS, Ajjan RA (2019) Double diabetes: a distinct high-risk group? Diabetes Obes Metab 21(12):2609\u20132618. https:\/\/doi.org\/10.1111\/dom.13848","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"6429_CR20","doi-asserted-by":"publisher","first-page":"e14529","DOI":"10.1111\/dme.14529","volume":"38","author":"R Helliwell","year":"2021","unstructured":"Helliwell R, Warnes H, Kietsiriroje N et al (2021) Body mass index, estimated glucose disposal rate and vascular complications in type 1 diabetes: beyond glycated haemoglobin. Diabet Med 38(5):e14529. https:\/\/doi.org\/10.1111\/dme.14529","journal-title":"Diabet Med"},{"key":"6429_CR21","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-0475","author":"R Sun","year":"2024","unstructured":"Sun R, Wang J, Li M et al (2024) Association of insulin resistance with cardiovascular disease and all-cause mortality in type 1 diabetes: systematic review and meta-analysis. Diabetes Care. https:\/\/doi.org\/10.2337\/dc24-0475","journal-title":"Diabetes Care"},{"issue":"4","key":"6429_CR22","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/09537104.2018.1535705","volume":"30","author":"EL Welch","year":"2019","unstructured":"Welch EL, Crooks MG, Hart SP (2019) Agreement between blood draw techniques for assessing platelet activation by flow cytometry. Platelets 30(4):530\u2013534. https:\/\/doi.org\/10.1080\/09537104.2018.1535705","journal-title":"Platelets"},{"key":"6429_CR23","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1538-7836.2009.03370.x","volume":"7","author":"B Nieswandt","year":"2009","unstructured":"Nieswandt B, Varga-Szabo D, Elvers M (2009) Integrins in platelet activation. J Thromb Haemost 7:206\u2013209. https:\/\/doi.org\/10.1111\/j.1538-7836.2009.03370.x","journal-title":"J Thromb Haemost"},{"issue":"4","key":"6429_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/rth2.12144","volume":"2","author":"EC Reddy","year":"2018","unstructured":"Reddy EC, Wang H, Christensen H et al (2018) Analysis of procoagulant phosphatidylserine-exposing platelets by imaging flow cytometry. Res Pract Thromb Haemost 2(4):736\u2013750. https:\/\/doi.org\/10.1002\/rth2.12144","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"6429_CR25","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1006\/bcmd.1999.0254","volume":"25","author":"JF Tait","year":"1999","unstructured":"Tait JF, Smith C, Wood BL (1999) Measurement of phosphatidylserine exposure in leukocytes and platelets by whole-blood flow cytometry with annexin V. Blood Cells Mol Dis 25(5):271\u2013278. https:\/\/doi.org\/10.1006\/bcmd.1999.0254","journal-title":"Blood Cells Mol Dis"},{"issue":"7","key":"6429_CR26","doi-asserted-by":"publisher","first-page":"102205","DOI":"10.1016\/j.rpth.2023.102205","volume":"7","author":"MS Hindle","year":"2023","unstructured":"Hindle MS, Cheah LT, Yates DM, Naseem KM (2023) Preanalytical conditions for multiparameter platelet flow cytometry. Res Pract Thromb Haemost 7(7):102205. https:\/\/doi.org\/10.1016\/j.rpth.2023.102205","journal-title":"Res Pract Thromb Haemost"},{"issue":"7","key":"6429_CR27","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1111\/jth.15330","volume":"19","author":"MS Hindle","year":"2021","unstructured":"Hindle MS, Spurgeon BEJ, Cheah LT, Webb BA, Naseem KM (2021) Multidimensional flow cytometry reveals novel platelet subpopulations in response to prostacyclin. J Thromb Haemost 19(7):1800\u20131812. https:\/\/doi.org\/10.1111\/jth.15330","journal-title":"J Thromb Haemost"},{"issue":"1","key":"6429_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cyto.b.21774","volume":"98","author":"BEJ Spurgeon","year":"2020","unstructured":"Spurgeon BEJ, Naseem KM (2020) Platelet flow cytometry: instrument setup, controls, and panel performance. Cytometry B Clin Cytom 98(1):19\u201327. https:\/\/doi.org\/10.1002\/cyto.b.21774","journal-title":"Cytometry B Clin Cytom"},{"issue":"7","key":"6429_CR29","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1080\/09537104.2018.1478073","volume":"29","author":"AL Frelinger III","year":"2018","unstructured":"Frelinger AL III (2018) Using flow cytometry to monitor glycoprotein IIb-IIIa activation. Platelets 29(7):670\u2013676. https:\/\/doi.org\/10.1080\/09537104.2018.1478073","journal-title":"Platelets"},{"issue":"12","key":"6429_CR30","doi-asserted-by":"publisher","first-page":"100372","DOI":"10.1016\/j.patter.2021.100372","volume":"2","author":"E Greene","year":"2021","unstructured":"Greene E, Finak G, D\u2019Amico LA et al (2021) New interpretable machine-learning method for single-cell data reveals correlates of clinical response to cancer immunotherapy. Patterns (N Y) 2(12):100372. https:\/\/doi.org\/10.1016\/j.patter.2021.100372","journal-title":"Patterns (N Y)"},{"issue":"2","key":"6429_CR31","doi-asserted-by":"publisher","first-page":"e687","DOI":"10.1002\/cpz1.687","volume":"3","author":"BEJ Spurgeon","year":"2023","unstructured":"Spurgeon BEJ, Frelinger AL III (2023) Platelet phenotyping by full spectrum flow cytometry. Curr Protoc 3(2):e687. https:\/\/doi.org\/10.1002\/cpz1.687","journal-title":"Curr Protoc"},{"issue":"1","key":"6429_CR32","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1038\/s41598-017-19126-8","volume":"8","author":"AL S\u00f6dergren","year":"2018","unstructured":"S\u00f6dergren AL, Ramstr\u00f6m S (2018) Platelet subpopulations remain despite strong dual agonist stimulation and can be characterised using a novel six-colour flow cytometry protocol. Sci Rep 8(1):1441. https:\/\/doi.org\/10.1038\/s41598-017-19126-8","journal-title":"Sci Rep"},{"issue":"24","key":"6429_CR33","doi-asserted-by":"publisher","first-page":"6345","DOI":"10.3390\/ijms20246345","volume":"20","author":"AIS Sobczak","year":"2019","unstructured":"Sobczak AIS, Stewart AJ (2019) Coagulatory defects in type-1 and type-2 diabetes. Int J Mol Sci 20(24):6345. https:\/\/doi.org\/10.3390\/ijms20246345","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6429_CR34","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1538-7836.2003.00525.x","volume":"2","author":"H Hu","year":"2004","unstructured":"Hu H, Li N, Yngen M, \u00d6stenson CG, Wall\u00e9n NH, Hjemdahl P (2004) Enhanced leukocyte\u2013platelet cross-talk in type 1 diabetes mellitus: relationship to microangiopathy. J Thromb Haemost 2(1):58\u201364. https:\/\/doi.org\/10.1111\/j.1538-7836.2003.00525.x","journal-title":"J Thromb Haemost"},{"issue":"1","key":"6429_CR35","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41467-018-03430-6","volume":"9","author":"L Ju","year":"2018","unstructured":"Ju L, McFadyen JD, Al-Daher S et al (2018) Compression force sensing regulates integrin \u03b1IIb\u03b23 adhesive function on diabetic platelets. Nat Commun 9(1):1087. https:\/\/doi.org\/10.1038\/s41467-018-03430-6","journal-title":"Nat Commun"},{"issue":"2","key":"6429_CR36","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1177\/107602960000600202","volume":"6","author":"MG van der Planken","year":"2000","unstructured":"van der Planken MG, Vertessen FJ, Vertommen J, Engelen W, Berneman ZN, De Leeuw I (2000) Platelet prothrombinase activity, a final pathway platelet procoagulant activity, is overexpressed in type 1 diabetes: no relationship with mean platelet volume or background retinopathy. Clin Appl Thromb Hemost 6(2):65\u201368. https:\/\/doi.org\/10.1177\/107602960000600202","journal-title":"Clin Appl Thromb Hemost"},{"issue":"7","key":"6429_CR37","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tips.2008.05.002","volume":"29","author":"P Gresele","year":"2008","unstructured":"Gresele P, Falcinelli E, Momi S (2008) Potentiation and priming of platelet activation: a potential target for antiplatelet therapy. Trends Pharmacol Sci 29(7):352\u2013360. https:\/\/doi.org\/10.1016\/j.tips.2008.05.002","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"6429_CR38","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1055\/s-0041-1735972","volume":"122","author":"A Veninga","year":"2022","unstructured":"Veninga A, Baaten C, De Simone I et al (2022) Effects of platelet agonists and priming on the formation of platelet populations. Thromb Haemost 122(5):726\u2013738. https:\/\/doi.org\/10.1055\/s-0041-1735972","journal-title":"Thromb Haemost"},{"issue":"6","key":"6429_CR39","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2337\/dc11-2040","volume":"35","author":"MF Lopes-Virella","year":"2012","unstructured":"Lopes-Virella MF, Baker NL, Hunt KJ et al (2012) High concentrations of AGE-LDL and oxidized LDL in circulating immune complexes are associated with progression of retinopathy in type 1 diabetes. Diabetes Care 35(6):1333\u20131340. https:\/\/doi.org\/10.2337\/dc11-2040","journal-title":"Diabetes Care"},{"issue":"1","key":"6429_CR40","doi-asserted-by":"publisher","first-page":"8623560","DOI":"10.1155\/2018\/8623560","volume":"2018","author":"SI Chisalita","year":"2018","unstructured":"Chisalita SI, Ludvigsson J (2018) Insulin-like growth factor-1 at diagnosis and during subsequent years in adolescents with type 1 diabetes. J Diabetes Res 2018(1):8623560. https:\/\/doi.org\/10.1155\/2018\/8623560","journal-title":"J Diabetes Res"},{"issue":"2","key":"6429_CR41","doi-asserted-by":"publisher","first-page":"503","DOI":"10.2337\/db15-0936","volume":"65","author":"F Zaccardi","year":"2016","unstructured":"Zaccardi F, Rizzi A, Petrucci G et al (2016) In vivo platelet activation and aspirin responsiveness in type 1 diabetes. Diabetes 65(2):503\u2013509. https:\/\/doi.org\/10.2337\/db15-0936","journal-title":"Diabetes"},{"issue":"8","key":"6429_CR42","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1016\/j.jtha.2023.03.044","volume":"21","author":"JL Mitchell","year":"2023","unstructured":"Mitchell JL, Dunster JL, Kriek N et al (2023) The rate of platelet activation determines thrombus size and structure at arterial shear. J Thromb Haemost 21(8):2248\u20132259. https:\/\/doi.org\/10.1016\/j.jtha.2023.03.044","journal-title":"J Thromb Haemost"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-025-06429-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-025-06429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T14:05:07Z","timestamp":1750255507000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-025-06429-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,30]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["6429"],"URL":"https:\/\/doi.org\/10.1007\/s00125-025-06429-z","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,30]]},"assertion":[{"value":"25 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors would like to thank the British Heart Foundation (BHF) and NIHR Leeds Biomedical Research Centre for their support for this study. Work in this manuscript was included in the PhD thesis Sagar, RC (2023). Characterisation of platelet function and pro-inflammatory phenotype in type 1 diabetes mellitus and double diabetes (Doctoral thesis, University of Leeds). Available from: .","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Acknowledgements"}},{"value":"Data will be provided by the corresponding author via email upon reasonable request","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"RCS was funded by the British Heart Foundation, grant code RG.LIGH.11843, including the data published in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"RCS undertook conceptualisation, study design, participant enrolment, experimental data collection, data analysis and writing (draft, review and editing). DMY contributed data analysis. SMP and NK both contributed to conceptualisation, study design, participant enrolment, data analysis and writing (review and editing). MSH, LTC and BAW provided experimental support, resources and writing (review and editing). RAA and KMN are co-senior authors. RAA provided conceptualisation, study design, funding acquisition, participant enrolment, data analysis and writing (review and editing). KMN provided conceptualisation, study design, funding acquisition, supervision and writing (review and editing). All authors critically appraised and approved the final manuscript. RCS, RAA and KMN are the guarantors of this work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}